A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00152230
Recruitment Status : Completed
First Posted : September 9, 2005
Last Update Posted : July 7, 2011
Information provided by:
Taiho Pharmaceutical Co., Ltd.

Brief Summary:
This is a controlled study designed to compare relapse-free survival and overall survival in patients receiving UFT with those in patients receiving surgery alone. Patients will be randomly assigned to surgery alone or surgery followed by UFT within 6 weeks after curative resection. To assess treatment efficacy, data on recurrence and survival will be collected for 5 years after enrollment of the last patient. To evaluate safety, data on adverse events will be collected for 12 months after the start of treatment.Evaluations will be separately done for colon cancer and rectal cancer.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: UFT (uracil, tegafur) Procedure: Surgery alone Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 900 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone in Patients With Dukes C Colorectal Cancer (NSAS-CC)
Study Start Date : October 1996
Actual Primary Completion Date : March 2006
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
UFT (uracil, tegafur)
Drug: UFT (uracil, tegafur)
to receive oral uracil-tegafur 400 mg square meter for one year
Surgery alone
Procedure: Surgery alone
Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.

Primary Outcome Measures :
  1. Relapse-free survival and overall survival [ Time Frame: every course for first three courses, then every other course ]

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: any time ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 20 to 75
  • Performance status 0 , 1, or 2 (ECOG)
  • Hematopoietic WBC ≥ 4,000/mm^3 Platelet ≥ 100,000/mm^3
  • Hepatic AST and ALT ≤ 2 times upper limit of normal(ULN) Total bilirubin ≤ 1.2mg/dL
  • Renal BUN ≤ 25mg/dL Creatinine ≤ 1.5mg/dL

Exclusion Criteria:

  • Prior anticancer treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00152230

National Cancer Center Hospital East
6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan
Sponsors and Collaborators
Taiho Pharmaceutical Co., Ltd.
Principal Investigator: Shigeaki Yoshida, MD National Cancer Center Hospital East

Publications of Results:
Other Publications:
Responsible Party: Taiho Pharmaceutical Co., Ltd. Identifier: NCT00152230     History of Changes
Other Study ID Numbers: 01023002
First Posted: September 9, 2005    Key Record Dates
Last Update Posted: July 7, 2011
Last Verified: July 2011

Keywords provided by Taiho Pharmaceutical Co., Ltd.:
Colorectal Cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents